TrialCancer chemotherapy and pharmacology2024

Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study.

Antoine Adenis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.